{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113883.3.3616.200.110.102.1015",
  "meta" : {
    "versionId" : "5",
    "lastUpdated" : "2022-07-13T01:02:20.000-04:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueString" : "Clinical Architecture"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2023-06-21"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2022-07-13"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.1015",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113883.3.3616.200.110.102.1015"
    }
  ],
  "version" : "20220713",
  "name" : "BamlanivimabEtesevimabAdministration",
  "title" : "Bamlanivimab / Etesevimab Administration",
  "status" : "active",
  "experimental" : false,
  "date" : "2023-06-21T18:16:37-04:00",
  "publisher" : "Clinical Architecture",
  "jurisdiction" : [
    {
      "extension" : [
        {
          "url" : "http://hl7.org/fhir/StructureDefinition/data-absent-reason",
          "valueString" : "UNKNOWN"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: This set of values contains terms related to intravenous administration of bamlanivimab / etesevimab.),(Data Element Scope: ),(Inclusion Criteria: Includes terms related to intravenous administration of bamlanivimab / etesevimab.),(Exclusion Criteria: Excludes terms related to administration of bamlanivimab alone.)",
  "compose" : {
    "include" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "concept" : [
          {
            "code" : "M0245",
            "display" : "Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring"
          },
          {
            "code" : "M0246",
            "display" : "Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the covid 19 public health emergency"
          },
          {
            "code" : "Q0245",
            "display" : "Injection, bamlanivimab and etesevimab, 2100 mg"
          }
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:45dfe562-fb18-4328-932d-f600e031d488",
    "timestamp" : "2023-06-29T15:53:23-04:00",
    "total" : 3,
    "offset" : 0,
    "parameter" : [
      {
        "name" : "count",
        "valueInteger" : 1000
      },
      {
        "name" : "offset",
        "valueInteger" : 0
      }
    ],
    "contains" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "M0245",
        "display" : "Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "M0246",
        "display" : "Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the covid 19 public health emergency"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2023",
        "code" : "Q0245",
        "display" : "Injection, bamlanivimab and etesevimab, 2100 mg"
      }
    ]
  }
}
